Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026)
Immunome (IMNM) reported Depreciation & Amortization (CF) of $603000.0 for Q1 2026, down 1.31% on a YoY basis from $611000.0 in Q1 2025, and down 4.13% quarter-over-quarter from $629000.0 in Q4 2025.
Immunome (IMNM) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Immunome has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $603000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 1.31% year-over-year to $603000.0; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 21.62% YoY), and the FY2025 full-year result was $2.5 million, up 57.37% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $603000.0, down from $629000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $637000.0 in Q2 2025, with the low at $73000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $323117.6 across 5 years, with a median of $157000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 63.99% — and 2024, when it soared 443.56%.
- Immunome's Depreciation & Amortization (CF) stood at $73000.0 in 2022, then soared by 106.85% to $151000.0 in 2023, then jumped by 198.01% to $450000.0 in 2024, then jumped by 39.78% to $629000.0 in 2025, then dropped by 4.13% to $603000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $603000.0 (Q1 2026), $629000.0 (Q4 2025), and $589000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - | 603,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 603,000.00 |
| Mar 31, 2026 | 603,000.00 |
| Dec 31, 2025 | 629,000.00 |
| Dec 31, 2025 | 629,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Jun 30, 2025 | 637,000.00 |
| Mar 31, 2025 | 611,000.00 |
| Mar 31, 2025 | 611,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 411,000.00 |
| Sep 30, 2024 | 411,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Mar 31, 2024 | 157,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |